Kidney damage is a serious complication affecting individuals with lupus, an autoimmune disease where immune B cells ...
Until biomarkers that can predict treatment response emerge, early and aggressive treatment is recommended in lupus nephritis ...
T-cell profiles derived from blood and renal biopsy may be novel biomarkers of lupus nephritis treatment response, study findings suggest.
Lupkynis is a medicine that is used for a specific kidney disease called lupus nephritis. Lupus nephritis is a kidney condition that affects people with systemic lupus erythematosus (SLE). SLE is an ...
Yale researchers have identified CD8+ T cells as a key driver of kidney damage in lupus, challenging the long-standing focus on B cells. The discovery may explain why some patients do not respond to ...
In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for identification and prediction of active lupus nephritis, (LN, lupus-related ...
At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will already have the inflammation-caused kidney disease lupus nephritis, which ...
Urinary soluble CD163 normalized to creatinuria may be used to predict active lupus nephritis and response to therapy. Measurement of urinary soluble CD163 normalized to creatinuria (usCD163/Cre) may ...
– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results